Ipamorelin
Ipamorelin is a pentapeptide GHRP that selectively stimulates growth hormone release without significant cortisol or prolactin elevation. It is frequently stacked with CJC-1295 for GH-axis research.
Overview
Ipamorelin is a five-amino-acid (pentapeptide) synthetic GHRP that activates the ghrelin receptor (GHS-R1a) to stimulate pulsatile GH release from the pituitary. Unlike older GHRPs (GHRP-2, GHRP-6), Ipamorelin has high selectivity for GH release with minimal concurrent elevation of cortisol, prolactin, or ACTH — a pharmacological profile that makes it appealing for isolated GH-axis research. Its half-life is approximately 2 hours, making two-to-three times daily administration common in research protocols. The CJC-1295 + Ipamorelin combination is one of the most frequently referenced GH-axis research stacks because the two peptides act on different receptor subtypes with complementary stimulatory mechanisms.
Related Terms
Related Peptide Profiles
Frequently asked questions
How selective is Ipamorelin compared to other GHRPs?+
Ipamorelin is considered highly selective — it stimulates GH release with minimal off-target effects on cortisol, prolactin, or ACTH, unlike GHRP-6 which causes notable cortisol and appetite increases.
What is the half-life of Ipamorelin?+
Ipamorelin has a half-life of approximately 2 hours, which is why research protocols commonly use two to three daily administrations to maintain pulsatile GH stimulation.
Can Ipamorelin be used without CJC-1295?+
Yes, Ipamorelin can be studied independently. However, the CJC-1295/Ipamorelin combination is more common in research because dual receptor pathway activation amplifies GH pulse magnitude.